Fenwal Executive Takes on Fresenius Leadership Role Post-Acquisition
Posted on December 19, 2012 @ 09:44 am
A mere four days after its acquisition by Fresenius Kabi AG was complete, Fenwal Inc.’s former vice president of business development, strategy and international marketing, Dean A. Gregory, was named president of medical devices at Fresenius Kabi North America.
In his new role, Gregory will continue to be responsible for North America sales and marketing for the Fenwal business, as well as the commercialization of a range of Fresenius Kabi medical devices for transfusion medicine and infusion therapy, which are used by hospitals as well as blood and plasma collection centers.
Gregory has more than 20 years of health care experience in sales, marketing, strategy and business development roles of increasing responsibility. He joined Fenwal in 2007 when the company was formed though a spin-off from Baxter International. He joined Baxter in 1991. He earned a master’s degree in business administration from DePaul University in Chicago, Ill., and a bachelor’s degree in biology from University of Illinois in the same city. He is also a member of AABB (formerly the American Association of Blood Banks), the International Society for Blood Transfusion, and the American Marketing
Based in Lake Zurich, Ill., Fenwal Inc. makes technology for blood separation, collection, filtration, storage and transfusion. The final cost of its sale to Fresenius was approximately $1.1 billion.
Fresenius Kabi’s product portfolio consists of a range of intravenous generic drugs, infusion therapies and clinical nutrition products as well as the medical devices for administering these products. The company’s North American headquarters are in Schaumburg, Ill.
Please visit our sister sites:
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.